Company / Shareholders' Equity
Axsome Therapeutics, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$88.3M
FY2025
5-year range
$15.6M / $191.0M
FY2021-FY2025
Trend
+54.9%
vs FY2024
Sector context
#175 of 213
Health Care
What the data says
Axsome Therapeutics, Inc.'s shareholders' equity of $88M is lower than 82% of companies in the Health Care sector (FY2025). Shareholders' Equity has fluctuated over the past 10 years, ranging from $937,921 in FY2018 to $191M in FY2023.
Based on SEC 10-K filings.
$88M in FY2025 with a 5-year CAGR of -4.9%.
Declined from $191M to $88M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -6.9%
- 5-Year CAGR
- -4.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 18% in Health CareTop 82% of 213This company $88.3M Sector average $2.5B
▼
-96.5% below sector average
Key checks
Key Insights
- 5-year CAGR of -4.9%, indicating a declining trend.
- In FY2025, shareholders' equity increased 54.9% year-over-year.
- Ranks #175 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $88.3M | +54.9% |
| FY2024 | $57.0M | -70.1% |
| FY2023 | $191.0M | +74.3% |
| FY2022 | $109.6M | +600.9% |
| FY2021 | $15.6M | -86.3% |
| FY2020 | $113.8M | -36.3% |
| FY2019 | $178.7M | +18955.2% |
| FY2018 | $937.9K | -94.4% |
| FY2017 | $16.7M | -22.5% |
| FY2016 | $21.6M | -53.6% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026